Akebia (AKBA) Therapeutics announced key corporate updates associated with its Vafseo commercial business and provided an outlook on upcoming milestones, including for its next anticipated growth driver, Akebia’s mid-stage rare kidney disease pipeline. 2025 Vafseo Achievements: Secured broad prescribing access for Vafseo encompassing approximately 275,000 patients on dialysis; Supported dialysis organizations’ implementation of modified dosing protocols or pilots now underway at the top 5 dialysis organizations; Completed enrollment in VOICE; Presented a post-hoc analysis of all-cause mortality and hospitalization from the Phase 3 INNO2VATE trials; Enrolled approximately 350 patients in VOCAL.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
- Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
- Akebia announces first patient dosed in Phase 2 trial of praliciguat
- Strategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
- Akebia Therapeutics Acquires Global Rights to ADX-097